Hi @JCoure
Please help me understand your logic BTG is certainly doing well and is in fact a competitor with their TheraSphere range and have shown some great sales growth for these. They also have quite a number of trials in the works for TheraSphere. So my questions why would you think that BTG competitive success in the same target market as SRX is an argument to suggest that SRX is too cheep?
As this current target market is competitive then I could argue that BTG success and SP rise is potentially at the detriment of SRX and their recent slow down in Dose sale growth is directly proportional to the decrease in the SP not withstanding some additional downside risk over the previous CEO activities and now pending ASIC and legal distractions.
Hi @JCoure Please help me understand your logic BTG is certainly...
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $57.30M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.0¢ | 13.0¢ | $16.27K | 120.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 112169 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 66337 | 2 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
13.0¢ |
Change
0.000 ( 7.14 %) |
||||
| Open | High | Low | Volume | ||
| 13.0¢ | 13.0¢ | 13.0¢ | 753 | ||
| Last updated 14.07pm 05/06/2024 ? | |||||
| SRX (ASX) Chart |